Why GE HealthCare’s FDA-cleared SIGNA MRI update is more about operations than image quality
GE HealthCare’s FDA-cleared SIGNA MRI systems signal a shift toward autonomous, helium-free imaging. Explore what this means for MRI operations.
Why ImmunityBio’s ANKTIVA European launch could reshape BCG-unresponsive bladder cancer care
ImmunityBio expands ANKTIVA into Europe with Accord Healthcare. Discover what this means for bladder cancer care, regulation, and real-world adoption.
What Belay Diagnostics’ Summit 2.0 results reveal about the future of CNS molecular diagnostics
Belay Diagnostics validates its Summit 2.0 CSF genomic assay, strengthening the clinical case for liquid biopsy in CNS cancers. Read the full analysis.
Why Sibel Health’s Aria sensor could change endpoint design in chronic refractory cough trials
Sibel Health secures FDA acceptance for its Aria cough sensor. Find out what this could change for chronic cough drug trials and digital endpoints.
Merlin CP-GEP becomes first NCCN-endorsed molecular test for early-stage melanoma risk assessment
NCCN guidelines now recommend Merlin CP-GEP for early-stage melanoma risk assessment. Discover what this changes for clinicians and diagnostics adoption.
Bimini Health Tech strengthens Puregraft franchise with SYNC as fat grafting scales globally
Bimini Health Tech secures FDA clearance for Puregraft SYNC. Explore what it changes for fat grafting workflows, adoption economics, and device strategy.
Devonian Health Group advances Thykamine with human liver-on-a-chip data targeting fibrosis in MASH
Devonian Health Group reports human liver-on-a-chip data for Thykamine in MASH. See what this means for fibrosis-focused drug development.
From ingredients to devices: what BON Natural Life Limited’s apple mask means for medical aesthetics innovation
Explore how BON Natural Life Limited’s bio-electronic apple polyphenol mask could reshape medical aesthetics if clinical data holds up.
Menopause-specific hair loss enters the clinical spotlight after KilgourMD trial data
KilgourMD’s phase II data challenges how menopause-related hair loss is studied and treated. See what changes and what clinicians will watch next.
Ambient-temperature RNA-ISH enters mainstream pathology as Molecular Instruments expands HCR Pro automation
Discover how Molecular Instruments’ ambient-temperature HCR Pro RNA-ISH on BOND-III could reshape clinical pathology automation and RNA diagnostics.